FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162628305> ?p ?o ?g. }

• W2162628305 endingPage "2171" @default.
• W2162628305 startingPage "2162" @default.
• W2162628305 abstract "Abstract Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL, Apo2 ligand) effectively kills multiple myeloma (MM) cells in vitro irrespective of refractoriness to dexamethasone and chemotherapy. Because clinical trials with this anticancer agent are expected shortly, we investigated the signaling pathway of TRAIL-induced apoptosis in MM. We detected rapid cleavage of caspases-8, -9, -3, and -6, as well as the caspase substrates poly(ADP-ribose) polymerase (PARP) and DNA fragmentation factor-45 (DFF45), but not caspase-10, upon TRAIL treatment in sensitive MM cells, pointing to caspase-8 as the apical caspase of TRAIL signaling in MM cells. These phenomena were not observed or were significantly delayed in TRAIL-resistant MM cells, suggesting that resistance may arise from inhibition at the level of caspase-8 activation. Higher levels of expression for various apoptosis inhibitors, including FLICE-inhibitory protein (FLIP), and lower procaspase-8 levels were present in TRAIL-resistant cells and sensitivity was restored by the protein synthesis inhibitor cycloheximide (CHX) and the protein kinase C (PKC) inhibitor bisindolylmaleimide (BIM), which both lowered FLIP and cellular inhibitor of apoptosis protein-2 (cIAP-2) protein levels. Forced expression of procaspase-8 or FLIP antisense oligonucleotides also sensitized TRAIL-resistant cells to TRAIL. Moreover, the cell permeable nuclear factor (NF)–κB inhibitor SN50, which sensitizes TRAIL-resistant cells to TRAIL, also inhibited cIAP2 protein expression. Finally, CHX, BIM, and SN50 facilitated the cleavage and activation of procaspase-8 in TRAIL-resistant cells, confirming that inhibition of TRAIL-induced apoptosis occurs at this level and that these agents sensitize MM cells by relieving this block. Our data set a framework for the clinical use of approaches that sensitize MM cells to TRAIL by agents that inhibit FLIP and cIAP-2 expression or augment caspase-8 activity." @default.
• W2162628305 created "2016-06-24" @default.
• W2162628305 creator A5010021766 @default.
• W2162628305 creator A5012712111 @default.
• W2162628305 creator A5032464400 @default.
• W2162628305 creator A5044162398 @default.
• W2162628305 creator A5081299017 @default.
• W2162628305 date "2002-03-15" @default.
• W2162628305 modified "2023-09-28" @default.
• W2162628305 title "Intracellular regulation of tumor necrosis factor–related apoptosis-inducing ligand–induced apoptosis in human multiple myeloma cells" @default.
• W2162628305 cites W1484817497 @default.
• W2162628305 cites W1500396877 @default.
• W2162628305 cites W1506642042 @default.
• W2162628305 cites W1599806854 @default.
• W2162628305 cites W1624903505 @default.
• W2162628305 cites W1970525491 @default.
• W2162628305 cites W1973109581 @default.
• W2162628305 cites W1979003732 @default.
• W2162628305 cites W1982661150 @default.
• W2162628305 cites W1982786027 @default.
• W2162628305 cites W1983398917 @default.
• W2162628305 cites W1991735848 @default.
• W2162628305 cites W1992310350 @default.
• W2162628305 cites W1996180957 @default.
• W2162628305 cites W1996594340 @default.
• W2162628305 cites W2004457956 @default.
• W2162628305 cites W2004952608 @default.
• W2162628305 cites W2009085926 @default.
• W2162628305 cites W2012173926 @default.
• W2162628305 cites W2017728303 @default.
• W2162628305 cites W2021413266 @default.
• W2162628305 cites W2022393030 @default.
• W2162628305 cites W2038055601 @default.
• W2162628305 cites W2038114873 @default.
• W2162628305 cites W2049312704 @default.
• W2162628305 cites W2055905844 @default.
• W2162628305 cites W2056217426 @default.
• W2162628305 cites W2062853648 @default.
• W2162628305 cites W2070359497 @default.
• W2162628305 cites W2082259697 @default.
• W2162628305 cites W2086247747 @default.
• W2162628305 cites W2089476060 @default.
• W2162628305 cites W2092508425 @default.
• W2162628305 cites W2104473825 @default.
• W2162628305 cites W2105441981 @default.
• W2162628305 cites W2106284224 @default.
• W2162628305 cites W2119326933 @default.
• W2162628305 cites W2130988210 @default.
• W2162628305 cites W2323955045 @default.
• W2162628305 cites W2334639861 @default.
• W2162628305 cites W4237888277 @default.
• W2162628305 cites W4250256124 @default.
• W2162628305 cites W42909849 @default.
• W2162628305 cites W76644046 @default.
• W2162628305 doi "https://doi.org/10.1182/blood.v99.6.2162" @default.
• W2162628305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11877293" @default.
• W2162628305 hasPublicationYear "2002" @default.
• W2162628305 type Work @default.
• W2162628305 sameAs 2162628305 @default.
• W2162628305 citedByCount "146" @default.
• W2162628305 countsByYear W21626283052012 @default.
• W2162628305 countsByYear W21626283052013 @default.
• W2162628305 countsByYear W21626283052014 @default.
• W2162628305 countsByYear W21626283052015 @default.
• W2162628305 countsByYear W21626283052016 @default.
• W2162628305 countsByYear W21626283052017 @default.
• W2162628305 countsByYear W21626283052021 @default.
• W2162628305 countsByYear W21626283052022 @default.
• W2162628305 crossrefType "journal-article" @default.
• W2162628305 hasAuthorship W2162628305A5010021766 @default.
• W2162628305 hasAuthorship W2162628305A5012712111 @default.
• W2162628305 hasAuthorship W2162628305A5032464400 @default.
• W2162628305 hasAuthorship W2162628305A5044162398 @default.
• W2162628305 hasAuthorship W2162628305A5081299017 @default.
• W2162628305 hasBestOaLocation W21626283051 @default.
• W2162628305 hasConcept C104317684 @default.
• W2162628305 hasConcept C12519072 @default.
• W2162628305 hasConcept C153911025 @default.
• W2162628305 hasConcept C17991360 @default.
• W2162628305 hasConcept C182979987 @default.
• W2162628305 hasConcept C190283241 @default.
• W2162628305 hasConcept C203014093 @default.
• W2162628305 hasConcept C2776591724 @default.
• W2162628305 hasConcept C2777408456 @default.
• W2162628305 hasConcept C2778128677 @default.
• W2162628305 hasConcept C31573885 @default.
• W2162628305 hasConcept C33195913 @default.
• W2162628305 hasConcept C3675279 @default.
• W2162628305 hasConcept C43759708 @default.
• W2162628305 hasConcept C48297814 @default.
• W2162628305 hasConcept C502942594 @default.
• W2162628305 hasConcept C55493867 @default.
• W2162628305 hasConcept C66008609 @default.
• W2162628305 hasConcept C82381507 @default.
• W2162628305 hasConcept C86803240 @default.
• W2162628305 hasConcept C95444343 @default.
• W2162628305 hasConcept C98424977 @default.
• W2162628305 hasConceptScore W2162628305C104317684 @default.

• next